Fracture risk in patients with different types of cancer

Acta Oncologica

Volumn 48, Issue 1, 2009, Pages 105-115

  Vestergaard, Peter ^a   Rejnmark, Lars ^a   Mosekilde, Leif ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CONTROLLED STUDY; FEMALE; FOREARM FRACTURE; FRACTURE; GALLBLADDER CANCER; HIP FRACTURE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PANCREAS CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SPINE FRACTURE;

AGED; BONE NEOPLASMS; CASE-CONTROL STUDIES; DENMARK; FEMALE; FRACTURES, BONE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASMS; RISK FACTORS;

EID: 58149093314     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802167490     Document Type: Article

References (50)

1. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005;16:707-11.
2. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:1179-81.
3. Utz JP, Melton III LJ, Kan SH, Riggs BL. Risk of osteoporotic fractures in women with breast cancer: A population-based cohort study. J Chron Dis 1987;40:105-13.
4. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996;276:1404-8.
5. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215-23.
6. Kristensen B, Ejlertsen B, Mouridsen HT, Andersen KW, Lauritzen JB. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 1996;39:321-6.
7. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. British J Cancer 1990;61:308-10.
8. Halton JM, Atkinson SA, Fraher L, Webber C, Gill GJ, Dawson S, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996;11:1774-83.
9. Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: Comparison of fracture risk with the General Practice Research Database. Pediatr Blood Cancer 2007;48:21-7.
10. Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 2004;22:1215-21.
11. Wagner LM, Neel MD, Pappo AS, Merchant TE, Poquette CA, Rao BN, et al. Fractures in pediatric Ewing sarcoma. J Pediatr Hematol Oncol 2001;23:568-71.
12. Brown SA, Guise TA. Cancer-associated bone disease. Curr Osteoporos Rep 2007;5:120-7.
13. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
14. Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 2003;29:471-88.
15. Wall JE, Kaste SC, Greenwald CA, Jenkins JJ, Douglass EC, Pratt CB. Fractures in children treated with radiotherapy for soft tissue sarcoma. Orthopedics 1996;19:657-64.
16. Theriault RL. Pathophysiology and implications of cancer treatment-induced bone loss. Oncology (WillistonPark) 2004;18:11-5.
17. van Leeuwen BL, Kamps WA, Jansen HW, Hoekstra HJ. The effect of chemotherapy on the growing skeleton. Cancer Treat Rev 2000;26:363-76.
18. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
19. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of morphine and opiates. J Intern Med 2006;260:76-87.
20. Yoshida A, Nakamura Y, Shimizu A, Harada M, Kameda Y, Nagano A, et al. Significance of the parathyroid hormone-related protein expression in breast carcinoma. Breast Cancer 2000;7:215-20.
21. Atkins CD. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2003;95:332-4.
22. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-93.
23. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-7.
24. Frank L. Epidemiology. When an entire country is a cohort. Science 2000;287:2398-9.
25. Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. Danish Medical Bulletin 1999;46:263-8.
26. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: A nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 2002;156:1-10.
27. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992;135:1019-28.
28. Capella D. Descriptive tools and analysis. In: Dukes MNG, ed. Drug Utilization Studies: Methods and Uses. Copenhagen: WHO Regional Publications, European Series No. 45; 1993. p 55-78.
29. Nielsen GL, Sørensen HT, Zhou W, Steffensen FH, Olsen J. The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med 1997;10:203-5.
30. Vestergaard P, Rejnmark L, Mosekilde L. Socioeconomic aspects of fractures within universal public healthcare: A nationwide case-control study from Denmark. Scand J Public Health 2006;34:371-7.
31. Klotzbuecher CM, Ross PD, Landsman PB, Abbott III TA, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39.
32. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int 2006;79:84-94.
33. van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Mineral Res 2000;15:993-1000.
34. Munk-Jørgensen P, Mortensen PB. The Danish Psychiatric Central Register. Danish Medical Bulletin 1997;44:82-4.
35. Miettinen OS. Theoretical epidemiology: Principles of occurrence research in medicine. New York: Wiley & Sons; 1985. p 1-359
36. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002;94:1867-75.
37. Grant WB. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res 2003;164:371-7.
38. Bischoff HA, Stähelin HB, Dick W, Akos R, Knecht M, Salis C, et al. Effects of vitamin D and calcium supplementation on falls: A randomized controlled trial. J Bone Miner Res 2003;18:343-51.
39. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. The Lancet 2007;370:657-66.
40. Vestergaard P, Mosekilde L. Fracture risk associated with smoking - a meta-analysis. J Intern Med 2003;254:572-83.
41. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005;257:374-84.
42. Nishigaki Y, Ohsaki Y, Toyoshima E, Kikuchi K. Increased serum and urinary levels of a parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients. Clin Cancer Res 1999;5:1473-81.
43. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
44. Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol 2004;172:529-32.
45. Dickman PW, Adolfsson J, Astrom K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 2004;172:2208-12.
46. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005;165:552-8.
47. Adami HO, Zack M, Kressner U, Persson I, Berglund A, Naessen T, et al. Hip fractures in women with breast cancer. Am J Epidemiol 1990;132:877-83.
48. Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol 2003;13:698-703.
49. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
50. Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr Blood Cancer 2007;48:21-7.